X
Jul 06, 2021 08:10 PM (GMT+8) · EqualOcean
Hoplatin announced that it is in the research product of batolizumab for Chinese patients with generalized myasthenia gravis (GMG) phase II study of positive results. The data of phase II study showed that bartolizumab showed better clinical improvement than placebo in terms of statistics and clinical benefits, as well as good safety and tolerability. Bartolizumab is expected to become a new choice to fill the current treatment gap of GMG patients. Phase III trials are expected to start in the second half of 2021.